ILIU Insider Trading Activity and SEC Form 4 Filings
ILIU insider trading summary
No open-market insider purchases or sales of Interleukin Genetics Inc (ILIU) have been reported on SEC Form 4 in the past 12 months.
Latest ILIU insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jul 29, 2016 | James M Weaver | Director | Buy | $10K (100,603 @ $0.10) |
| Jul 29, 2016 | Mark B Carbeau | Chief Executive Officer | Buy | $10K (100,603 @ $0.10) |
| Jul 29, 2016 | Stephen J. DiPalma | Interim CFO | Buy | $10K (100,603 @ $0.10) |
| Jul 29, 2016 | Anthony A. Florence Jr. | 10% Owner | Buy | $2.0M (20,120,724 @ $0.10) |
| Jul 29, 2016 | Krishna Kittu Kolluri | 10% Owner | Buy | $2.0M (20,120,724 @ $0.10) |
| Jul 29, 2016 | Scott D Sandell | 10% Owner | Buy | $2.0M (20,120,724 @ $0.10) |
| Jul 29, 2016 | Ravi Viswanathan | 10% Owner | Buy | $2.0M (20,120,724 @ $0.10) |
| Jul 29, 2016 | Bay City Capital LLC | 10% Owner | Buy | $56K (564,386 @ $0.10) |
| Jul 29, 2016 | Peter J Barris | 10% Owner | Buy | $2.0M (20,120,724 @ $0.10) |
| Jul 29, 2016 | Kenneth S Kornman | President and CSO | Buy | $2K (25,150 @ $0.10) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.